Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeBIOTECHNOLOGYOrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

November 20, 2020

OrganaBio has begun construction on its current Good Manufacturing Practices (cGMP) manufacturing facility for cell and gene therapy manufacturing.

A Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.

“OrganaBio’s mission is to supply cell and gene therapy companies with mission-critical, but hard to procure resources that are needed to advance therapeutic programs,” Justin Irizarry, CEO of OrganaBio, said in a statement. “We are addressing broad supply chain challenges through an innovative portfolio of products and services that offer both preclinical and cGMP solutions for our customers.” Without clinical-grade starting materials and an accessible manufacturing solution, therapeutic developers cannot advance their program into a clinical phase.”

The company has partnered with Flad Architects and DPR Construction, leading Life Sciences architecture and construction firms, respectively, to design and build the facility, housed in a brand-new commercial business park, just 10 miles north of the Miami International Airport.

“We are excited about OrganaBio’s cGMP 19,000 square foot manufacturing facility which is set to create a large amount of lab space in the County that, in turn, will continue to grow Miami’s life sciences ecosystem,” said Michael A. Finney, President & CEO, the Miami-Dade Beacon Council. “Miami is already home to several universities actively participating in biomedical research, and OrganaBio’s new cGMP lab space will foster continued academic and commercial innovation.”

OrganaBio’s manufacturing solution will offer ready access to its portfolio of birth tissue- and adult tissue-derived cellular starting materials and expertise in cGMP manufacturing, Quality Assurance, Quality Control, and Regulatory Affairs to its customers and partners.

These resources will accelerate each therapeutics developer’s path to clinical translation and commercialization. Phase I of the cGMP manufacturing facility is slated to open Q3 2021 and will include process development space, 1-2 ISO7 cleanrooms, a QC laboratory and support spaces. The OrganaBio portfolio of cGMP cell products is subsequently slated to launch in Q4 2021.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy